GlaxoSmithKline

Live  

GlaxoSmithKline (GSK) is a multinational pharmaceutical and healthcare company headquartered in Brentford, London. The company was formed in 2000 through the merger of British company Glaxo Wellcome and American company SmithKline Beecham. It is one of the largest pharmaceutical companies in the world and is focused on the research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products.
History:
The history of GlaxoSmithKline can be traced back to the establishment of two independent companies: Joseph Nathan and Co. in New Zealand in 1873 and Burroughs Wellcome & Company in the UK in 1880. In 1995, Glaxo Wellcome PLC was formed through the merger of Glaxo and Burroughs Wellcome. SmithKline Beecham PLC was formed in 1989 through the merger of SmithKline Beckman Corporation and Beecham Group PLC. In 2000, the two companies merged to form GlaxoSmithKline.
Products:
GSK's product portfolio includes prescription medicines, vaccines, and consumer healthcare products. Its prescription medicines cover a broad range of therapeutic areas, including respiratory, HIV, oncology, and neurosciences. The company also offers vaccines for diseases such as influenza, meningitis, and shingles. Its consumer healthcare products include over-the-counter medicines, oral care, nutrition, and skin health products.
Research and Development:
GSK has a strong focus on research and development (R&D) and invests heavily in this area. The company has R&D facilities in the UK, US, Belgium, and China, among others. Its R&D efforts are focused on discovering and developing new medicines and vaccines for a wide range of diseases and conditions. GSK collaborates with academic institutions, governments, and other industry partners to advance its research efforts.
Corporate Responsibility:
GSK is committed to operating ethically and responsibly, with a focus on sustainability and corporate social responsibility. The company has various initiatives in place to reduce its environmental impact and improve access to healthcare for underserved populations. It also has policies in place to ensure ethical business practices and compliance with laws and regulations.
Financials:
In 2020, GSK reported revenues of £34 billion and a net income of £5.5 billion. The company employs over 100,000 people globally and has a presence in over 150 countries. Its primary stock exchange listings are on the London Stock Exchange and the New York Stock Exchange.
Partnerships:
GSK has formed partnerships with various organizations to further its research and development efforts, expand its product portfolio, and improve access to healthcare. Some notable collaborations include:
- Joint ventures with Pfizer in the areas of consumer healthcare and HIV treatment
- Collaboration with Sanofi to develop a COVID-19 vaccine
- Partnership with Innoviva to develop respiratory treatments
- Collaboration with Vir Biotechnology to develop pandemic treatments
- Partnership with the Bill & Melinda Gates Foundation to develop vaccines for malaria and tuberculosis
Summary:
GlaxoSmithKline is a multinational pharmaceutical and healthcare company focused on research, development, and marketing of prescription medicines, vaccines, and consumer healthcare products. It has a strong history and presence in the market, with a commitment to corporate responsibility and ethical business practices. The company has a diverse range of products and partnerships that contribute to its strong financial performance.

GlaxoSmithKline, or GSK for short, is a big company that helps keep people healthy. They create medicines and vaccines, which are special shots that help prevent sickness. You know how sometimes you might go to the doctor and get a flu shot? That’s a type of vaccine, and GSK makes some of those.
GSK makes money by selling these medicines and vaccines to hospitals, pharmacies, and doctors all around the world. When someone is sick and needs medicine, or when a child gets a vaccine to stay healthy, GSK earns money. They also do research to create new medicines, which can help even more people. If they discover a really good new medicine, they can sell it for many years, which helps them make even more money.
One reason GSK is successful is that they focus a lot on research and development. This means they spend time and money to find new and better ways to treat and prevent diseases, which makes people trust them. Also, health is super important, so there’s always a need for good medicines and vaccines.
In the future, GSK will likely stay successful because people will always need help staying healthy. As more diseases may come up, GSK will keep trying to find new ways to fight them. Plus, they are working on technology and better ways to deliver medicines, so they can help even more people.

VGhlcmUgYX JlIHNldmVy YWwga2V5IG ZhY3RvcnMg dGhhdCBtYW tlIEdsYXhv U21pdGhLbG luZSAoR1NL KSBhIHVuaX F1ZSBhbmQg c3BlY2lhbC Bjb21wYW55 Ojxicj4xLi BTaXplIGFu ZCBTY29wZT ogR1NLIGlz IG9uZSBvZi B0aGUgbGFy Z2VzdCBwaG FybWFjZXV0 aWNhbCBjb2 1wYW5pZXMg aW4gdGhlIH dvcmxkLCB3 aXRoIG9wZX JhdGlvbnMg aW4gb3Zlci AxNTAgY291 bnRyaWVzIG FuZCBhIHZh c3QgcG9ydG ZvbGlvIG9m IHByb2R1Y3 RzIHNwYW5u aW5nIHByZX NjcmlwdGlv biBtZWRpY2 luZXMsIGNv bnN1bWVyIG hlYWx0aGNh cmUsIGFuZC B2YWNjaW5l cy48YnI+Mi 4gSGlzdG9y eSBhbmQgTG VnYWN5OiBH U0sgaGFzIG EgcmljaCBo aXN0b3J5IG RhdGluZyBi YWNrIHRvIH RoZSAxOXRo IGNlbnR1cn ksIHdpdGgg dGhlIG1lcm dlciBvZiBH bGF4b1dlbG xjb21lIGFu ZCBTbWl0aE tsaW5lIEJl ZWNoYW0gaW 4gMjAwMCBz b2xpZGlmeW luZyBpdHMg cG9zaXRpb2 4gYXMgYSBt YWpvciBwbG F5ZXIgaW4g dGhlIGhlYW x0aGNhcmUg aW5kdXN0cn kuPGJyPjMu IFJlc2Vhcm NoIGFuZCBE ZXZlbG9wbW VudDogSW5u b3ZhdGlvbi BhbmQgcmVz ZWFyY2ggYX JlIGF0IHRo ZSBoZWFydC BvZiBHU0sn cyBidXNpbm Vzcywgd2l0 aCBzaWduaW ZpY2FudCBp bnZlc3RtZW 50cyBtYWRl IGluIGRpc2 NvdmVyaW5n IGFuZCBkZX ZlbG9waW5n IG5ldyBtZW RpY2luZXMg dG8gbWVldC B1bm1ldCBt ZWRpY2FsIG 5lZWRzLjxi cj40LiBDb2 1taXRtZW50 IHRvIEdsb2 JhbCBIZWFs dGg6IEdTSy dzIG1pc3Np b24gaXMgdG 8gaW1wcm92 ZSB0aGUgcX VhbGl0eSBv ZiBodW1hbi BsaWZlIGJ5 IGVuYWJsaW 5nIHBlb3Bs ZSB0byBkby Btb3JlLCBm ZWVsIGJldH RlciwgYW5k IGxpdmUgbG 9uZ2VyLiBU aGUgY29tcG FueSBpcyBk ZWRpY2F0ZW QgdG8gYWRk cmVzc2luZy BnbG9iYWwg aGVhbHRoIG NoYWxsZW5n ZXMsIHN1Y2 ggYXMgaW5m ZWN0aW91cy BkaXNlYXNl cyBhbmQgYW NjZXNzIHRv IGhlYWx0aG NhcmUgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMuPG JyPjUuIERp dmVyc2UgUG 9ydGZvbGlv OiBHU0sgaG FzIGEgZGl2 ZXJzZSBwb3 J0Zm9saW8g b2YgcHJvZH VjdHMsIGlu Y2x1ZGluZy BtYXJrZXQt bGVhZGluZy BicmFuZHMg c3VjaCBhcy BBZHZhaXIs IFNlbnNvZH luZSwgYW5k IEZsb25hc2 UuIEl0IGFs c28gaGFzIG Egc3Ryb25n IHBpcGVsaW 5lIG9mIHBv dGVudGlhbC BuZXcgbWVk aWNpbmVzIG FuZCB2YWNj aW5lcyBpbi B2YXJpb3Vz IHN0YWdlcy BvZiBkZXZl bG9wbWVudC 48YnI+Ni4g Q29ycG9yYX RlIFJlc3Bv bnNpYmlsaX R5OiBHU0sg aXMgY29tbW l0dGVkIHRv IGNvbmR1Y3 RpbmcgYnVz aW5lc3Mgcm VzcG9uc2li bHkgYW5kIG V0aGljYWxs eSwgd2l0aC BhIGZvY3Vz IG9uIHN1c3 RhaW5hYmls aXR5LCBlbn Zpcm9ubWVu dGFsIHN0ZX dhcmRzaGlw LCBhbmQgaW 1wcm92aW5n IGFjY2Vzcy B0byBoZWFs dGhjYXJlIG ZvciB1bmRl cnNlcnZlZC Bwb3B1bGF0 aW9ucy48Yn I+Ny4gQ3Vs dHVyZSBhbm QgVmFsdWVz OiBHU0sgcH JpZGVzIGl0 c2VsZiBvbi BpdHMgZGl2 ZXJzZSBhbm QgaW5jbHVz aXZlIHdvcm twbGFjZSBj dWx0dXJlLC BndWlkZWQg YnkgYSBzZX Qgb2YgY29y ZSB2YWx1ZX MgdGhhdCBw cmlvcml0aX plIGludGVn cml0eSwgcm VzcGVjdCBm b3IgcGVvcG xlLCBhbmQg dHJhbnNwYX JlbmN5Ljxi cj5PdmVyYW xsLCBHU0sn cyBzaXplLC BoaXN0b3J5 LCBmb2N1cy BvbiBpbm5v dmF0aW9uIG FuZCBnbG9i YWwgaGVhbH RoLCBkaXZl cnNlIHBvcn Rmb2xpbywg Y29tbWl0bW VudCB0byBj b3Jwb3JhdG UgcmVzcG9u c2liaWxpdH ksIGFuZCBz dHJvbmcgY3 VsdHVyZSBt YWtlIGl0IG EgdW5pcXVl IGFuZCBlc3 RlZW1lZCBj b21wYW55IG luIHRoZSBw aGFybWFjZX V0aWNhbCBp bmR1c3RyeS 4=

R2xheG9TbW l0aEtsaW5l IChHU0spIG lzIGEgZ2xv YmFsIHBoYX JtYWNldXRp Y2FsIGFuZC BoZWFsdGhj YXJlIGNvbX BhbnkgZm9j dXNlZCBvbi BpbXByb3Zp bmcgdGhlIG hlYWx0aCBh bmQgd2VsbC 1iZWluZyBv ZiBwZW9wbG UgYXJvdW5k IHRoZSB3b3 JsZC4gVGhl IGNvbXBhbn kncyBidXNp bmVzcyBtb2 RlbCBpcyBi YXNlZCBvbi Bmb3VyIGtl eSBjb21wb2 5lbnRzOiA8 YnI+MS4gUm VzZWFyY2gg YW5kIERldm Vsb3BtZW50 IChSJkQpOi BHU0sgaW52 ZXN0cyBoZW F2aWx5IGlu IFImRCB0by BkZXZlbG9w IG5ldyBtZW RpY2luZXMs IHZhY2Npbm VzLCBhbmQg Y29uc3VtZX IgaGVhbHRo Y2FyZSBwcm 9kdWN0cy4g VGhlIGNvbX BhbnkgaGFz IHJlc2Vhcm NoIGNlbnRl cnMgYW5kIH BhcnRuZXJz aGlwcyB3b3 JsZHdpZGUg dG8gZHJpdm UgaW5ub3Zh dGlvbiBhbm QgaW1wcm92 ZSBwYXRpZW 50IGhlYWx0 aCBvdXRjb2 1lcy48YnI+ Mi4gQ29tbW VyY2lhbGl6 YXRpb24gYW 5kIE1hcmtl dGluZzogR1 NLIHNlbGxz IGl0cyBwcm 9kdWN0cyB0 byBwYXRpZW 50cywgaGVh bHRoY2FyZS Bwcm9mZXNz aW9uYWxzLC BhbmQgb3Ro ZXIgY3VzdG 9tZXJzIHRo cm91Z2ggYS B2YXJpZXR5 IG9mIGNoYW 5uZWxzLiBU aGlzIGluY2 x1ZGVzIHRy YWRpdGlvbm FsIHNhbGVz IGFuZCBtYX JrZXRpbmcg ZWZmb3J0cy wgYXMgd2Vs bCBhcyBkaW dpdGFsIGFu ZCBlLWNvbW 1lcmNlIGlu aXRpYXRpdm VzLjxicj4z LiBTdHJhdG VnaWMgUGFy dG5lcnNoaX BzOiBHU0sg Y29sbGFib3 JhdGVzIHdp dGggYSByYW 5nZSBvZiBw YXJ0bmVycy wgaW5jbHVk aW5nIGFjYW RlbWljIGlu c3RpdHV0aW 9ucywgYmlv dGVjaCBjb2 1wYW5pZXMs IGFuZCBvdG hlciBwaGFy bWFjZXV0aW NhbCBjb21w YW5pZXMsIH RvIGFkdmFu Y2UgaXRzIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCBlZmZvcn RzLjxicj40 LiBEaXZlcn NpZmllZCBQ b3J0Zm9saW 86IEdTSyBv cGVyYXRlcy BpbiB0aHJl ZSBtYWluIG FyZWFzIC0g cGhhcm1hY2 V1dGljYWxz LCB2YWNjaW 5lcywgYW5k IGNvbnN1bW VyIGhlYWx0 aGNhcmUuIF RoaXMgZGl2 ZXJzaWZpZW QgcG9ydGZv bGlvIGhlbH BzIG1pdGln YXRlIHJpc2 tzIGFuZCBh bGxvd3MgdG hlIGNvbXBh bnkgdG8gYm VuZWZpdCBm cm9tIHRoZS BkaWZmZXJl bnQgZ3Jvd3 RoIHRyZW5k cyBhbmQgcm VndWxhdG9y eSBsYW5kc2 NhcGVzIGFj cm9zcyB0aG VzZSBzZWN0 b3JzLjxicj 5JbiBhZGRp dGlvbiwgR1 NLIGhhcyBh IHN0cm9uZy Bmb2N1cyBv biBzdXN0YW luYWJpbGl0 eSBhbmQgc2 9jaWFsIHJl c3BvbnNpYm lsaXR5LCBp bnRlZ3JhdG luZyB0aGVz ZSBwcmluY2 lwbGVzIGlu dG8gaXRzIG J1c2luZXNz IG9wZXJhdG lvbnMgYW5k IGRlY2lzaW 9uLW1ha2lu Zy4gVGhlIG NvbXBhbnkg aXMgYWxzby Bjb21taXR0 ZWQgdG8gcH JpY2luZyBp dHMgcHJvZH VjdHMgcmVz cG9uc2libH kgYW5kIGVu c3VyaW5nIG FjY2VzcyB0 byBtZWRpY2 luZXMgaW4g ZGV2ZWxvcG luZyBjb3Vu dHJpZXMu

AI can indeed pose potential threats to GlaxoSmithKline (GSK) in various ways related to products, services, and competitive positioning:
1. Substitution: AI can enable the development of new pharmaceuticals or therapies that outperform existing GSK products. For example, AI-driven drug discovery processes can lead to faster identification of effective compounds, creating competition from companies that leverage these technologies successfully. If AI can produce superior treatment options, patients and healthcare providers may opt for alternatives instead of GSK’s offerings.
2. Disintermediation: AI could facilitate more direct relationships between patients and healthcare solutions, reducing the need for traditional pharmaceutical sales channels. The rise of telemedicine and AI-based diagnostics might enable patients to access personalized treatment plans directly, which could diminish GSK’s role as a traditional pharmaceutical provider and shift the focus toward tech-driven health solutions.
3. Margin Pressure: As AI enhances R&D efficiency and reduces costs for competitors, GSK may face margin pressures. Competitors using AI can develop and bring products to market more quickly and cost-effectively, allowing them to price their drugs more competitively. If GSK cannot match these efficiencies, it may need to lower its prices to retain market share, impacting profit margins.
In summary, while AI presents opportunities for GSK, it also poses significant risks in terms of substitution, disintermediation, and margin pressures that the company will need to navigate to maintain its competitive position.

The sensitivity of GlaxoSmithKline’s earnings, cash flow, and valuation to changes in interest rates can be analyzed through several key channels:
1. Cost of Debt: If interest rates rise, the cost of borrowing for GlaxoSmithKline may increase. This can lead to higher interest expenses, which can reduce net earnings. If the company has significant debt, even a small increase in rates can materially impact its earnings.
2. Discount Rate: Valuation models, such as discounted cash flow (DCF), use a discount rate that typically incorporates interest rates. An increase in interest rates raises the discount rate, which reduces the present value of future cash flows. As a result, the overall valuation of the company could decline.
3. Consumer Spending: Higher interest rates can lead to decreased consumer spending as borrowing becomes more expensive. This could affect GlaxoSmithKline’s sales, especially for over-the-counter products or consumer healthcare segments.
4. Research and Development: GlaxoSmithKline invests heavily in research and development. In a high-interest-rate environment, funding these projects through debt may become more costly, potentially leading to cuts in R&D budgets or delays in project timelines.
5. Portfolio Sensitivity: The specific product portfolio and pipeline developments of GlaxoSmithKline also play a role. If the company relies heavily on drugs with patent expirations or needs continuous investment for new products, changing interest rates may impact their financial strategies.
6. Investment and Expansion: Higher interest rates could dampen GlaxoSmithKline’s willingness or ability to invest in expansion, acquisitions, or new technologies, affecting long-term growth potential.
In summary, changes in interest rates can have multifaceted effects on GlaxoSmithKline’s earnings, cash flow, and valuation. Generally, rising interest rates pose risks due to increased borrowing costs and can lead to a lower valuation, while declining rates might provide a more favorable environment for the company’s financial performance.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3Mvbn VkRDBMNmt1 eFY4RFdsVX RKQjgud2Vi cCIgYWx0PS JHbGF4b1Nt aXRoS2xpbm UiIHRpdGxl PSJHbGF4b1 NtaXRoS2xp bmUiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2xh eG9TbWl0aE tsaW5lPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg4p yN77iPIFNp Z24gdXAgdG 8gZ2V0IDxp PiJUaGUgQ2 hlY2tsaXN0 IFZhbHVlIE ludmVzdG9y IOKAlCBBIF NtYXJ0ZXIg V2F5IHRvIF BpY2sgU3Rv Y2tzIjwvaT 4gZm9yIGZy ZWUKICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9w PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPCEt LQogICAgIC AgICAgICAg ICAgICAgIC AgICA8ZGl2 IHN0eWxlPS dtYXJnaW4t dG9wOiAxMn B4OyBmb250 LXNpemU6ID EzcHg7IGNv bG9yOiAjND Q0Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIG5vdy BhbmQgZ2V0 IG91ciBmcm VlIGVCb29r IAogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PGI+VGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrczwvYj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIC0tPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDE2cHg7 IGZvbnQtc2 l6ZTogMTRw eDsgY29sb3 I6ICM0NDQ7 IGZvbnQtZm FtaWx5OiAt YXBwbGUtc3 lzdGVtLCBC bGlua01hY1 N5c3RlbUZv bnQsIFNlZ2 9lIFVJLCBS b2JvdG8sIE hlbHZldGlj YSBOZXVlLC BzYW5zLXNl cmlmOyBsaW 5lLWhlaWdo dDogMS42Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BIYXZlIHlv dSBoZWFyZC BhYm91dCBv dXIgc2hvcn QgPHN0cm9u ZyBzdHlsZT 0nZm9udC13 ZWlnaHQ6ID YwMDsnPkRh aWx5IFZpZG VvIE5ld3Ns ZXR0ZXI8L3 N0cm9uZz4/ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 YSBocmVmPS dodHRwczov L3d3dy5pbn NpZ2h0ZnVs dmFsdWUuY2 9tL25ld3Ns ZXR0ZXIucG hwJyB0YXJn ZXQ9J19ibG Fuaycgc3R5 bGU9J2NvbG 9yOiAjMDA3 QkZGOyB0ZX h0LWRlY29y YXRpb246IG 5vbmU7IGZv bnQtd2VpZ2 h0OiA1MDA7 IG1hcmdpbi 1sZWZ0OiA2 cHg7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BGaW5kIG91 dCBtb3JlCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 E+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgICAg ICAgICAtLT 4KICAgICAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg CiAgICAgIC AgCiAgICAg ICAgPHNwYW 4gY2xhc3M9 J2JsdXJyZW QtdGV4dCc+ CiAgICAgIC AgICAgIE1T NGdSMnhoZU cgOVRiV2ww YUV0cyBhVz VsSUdseklH IEVnUW5KcG RHbHogYUNC dGRXeDBhVy A1aGRHbHZi bUZzIElIQm 9ZWEp0WVcg TmxkWFJwWT JGcyBJR052 YlhCaGJuIG tzSUhkcGRH Z2cgYUdWaF pIRjFZWCBK MFpYSnpJR2 x1IElFeHZi bVJ2Ymkgd2 dSVzVuYkdG dSBaQzQ4WW 5JK01pIDRn VkdobElHTn YgYlhCaGJu a2dhRyBGek lHRWdiRzl1 IFp5Qm9hWE 4wYjMgSjVM Q0JrWVhScC BibWNnWW1G amF5IEIwYn lCaElIQm8g WVhKdFlXTj VJRyA5d1pX NWxaQ0JpIG VTQktiM05s Y0cgZ2dUbU YwYUdGdSBJ R2x1SUU1bG R5IEJhWldG c1lXNWsgSU dsdUlERTRN eiBBdVBHSn lQak11IElG Um9aU0JqYj IgMXdZVzU1 SUhkaCBjeU JtYjNKdFlX IHhzZVNCbW IzVnUgWkdW a0lHbHVJRC BFNU1EWWdZ bmtnIFNtOX paWEJvSUUg VmtkMkZ5Wk NCTyBZWFJv WVc0Z1lXID VrSUdocGN5 QmkgY205MG FHVnlMVyBs dUxXeGhkeX dnIFZHaHZi V0Z6SUUgaH ZiR3h2ZDJG NSBMQ0JoY3 lCaElIIE50 WVd4c0lIQm 8gWVhKdFlX TjVJRyBsdU lFeHZibVJ2 IGJpNDhZbk krTkMgNGdW R2hsSUc1aC BiV1VnUjJ4 aGVHIDhnWT I5dFpYTWcg Wm5KdmJTQj BhRyBVZ1pt bHljM1FnIG NISnZaSFZq ZEMgQjBhR0 YwSUhSbyBa U0JqYjIxd1 lXIDU1SUhC eWIyUjEgWT JWa0xDQjNh RyBsamFDQj NZWE1nIFlT QmtjbWxsWk MgQnRhV3hy SUhCeSBiMl IxWTNRZ1ky IEZzYkdWa0 lFZHMgWVho dkxqeGljai A0MUxpQkhi R0Y0IGJ5Qn RaWEpuWlcg UWdkMmwwYU NCWCBaV3hz WTI5dFpTIE JwYmlBeE9U azEgSUhSdk lHWnZjbSAw Z1IyeGhlRz hnIFYyVnNi R052YlcgVX NJSGRvYVdO byBJSFJvWl c0Z2JXIFZ5 WjJWa0lIZH AgZEdnZ1Uy MXBkRyBoTG JHbHVaU0JD IFpXVmphR0 Z0SUcgbHVJ REl3TURBZy BkRzhnWm05 eWJTIEJIYk dGNGIxTnQg YVhSb1MyeH BibSBVdVBH SnlQall1IE lFZHNZWGh2 VTIgMXBkR2 hMYkdsdSBa U0JwY3lCam RYIEp5Wlc1 MGJIa2cgYj I1bElHOW1J SCBSb1pTQn NZWEpuIFpY TjBJSEJvWV ggSnRZV05s ZFhScCBZMk ZzSUdOdmJY IEJoYm1sbG N5QnAgYmlC MGFHVWdkMi A5eWJHUXNJ SGRwIGRHZ2 djbVYyWlcg NTFaU0J2Wm lCdiBkbVZ5 SUNRME1TIE JpYVd4c2FX OXUgSUdsdU lESXdNaiBB dVBHSnlQam N1IElGUm9a U0JqYjIgMX dZVzU1SUds eiBJR0VnYl dGcWIzIEln Y0hKdlpIVm ogWlhJZ2Iy WWdkbSBGal kybHVaWE1z IElHTnZibk 4xYlcgVnlJ R2hsWVd4MC BhR05oY21V Z2NIIEp2Wk hWamRITXMg SUdGdVpDQn djbSBWelkz SnBjSFJwIG IyNGdiV1Zr YVcgTnBibV Z6TENCaCBi bVFnYVhRZ2 FHIEZ6SUdF Z2NISmwgYz JWdVkyVWdh VyA0Z2IzWm xjaUF4IE5U QWdZMjkxYm 4gUnlhV1Z6 TGp4aSBjaj Q0TGlCSGJH IEY0YjFOdG FYUm8gUzJ4 cGJtVWdhRy BGeklHRWdi Rzl1IFp5Qm 9hWE4wYjMg SjVJRzltSU hOcCBaMjVw Wm1sallXID UwSUhOamFX VnUgZEdsbW FXTWdZVyBO b2FXVjJaVz FsIGJuUnpM Q0JwYm0gTn NkV1JwYm1j ZyBkR2hsSU dSbGRtIFZz YjNCdFpXNT AgSUc5bUlI UnlaVyBGMG JXVnVkSE1n IFptOXlJRW hKVmkgd2dh VzVtYkhWbC BibnBoTENC aGJtIFFnYl dGc1lYSnAg WVM0OFluSS tPUyA0Z1ZH aGxJR052IG JYQmhibmtn YUcgRnpJR0 ZzYzI4ZyBZ bVZsYmlCcG JuIFp2Ykha bFpDQnAgYm lCelpYWmxj bSBGc0lHaH BaMmd0IGNI SnZabWxzWl MgQnNaV2Ro YkNCaiBZWE 5sY3l3Z2FX IDVqYkhWa2 FXNW4gSUdF Z0pETWdZbS Bsc2JHbHZi aUJ6IFpYUj BiR1Z0Wlcg NTBJR1p2Y2 lCcCBiR3hs WjJGc2JIIG tnY0hKdmJX OTAgYVc1bk lHTmxjbiBS aGFXNGdaSE oxIFozTWdZ VzVrSUcgRW djMlYwZEd4 bCBiV1Z1ZE NCM2FYIFJv SUhSb1pTQl YgVXlCbmIz WmxjbSA1dF pXNTBJR1p2 IGNpQWtOel V3SUcgMXBi R3hwYjI0Zy BabTl5SUcx aGJuIFZtWV dOMGRYSnAg Ym1jZ1lXNW tJSCBGMVlX eHBkSGtnIF kyOXVkSEp2 YkMgQndjbT lpYkdWdCBj eUJoZENCaE lIIEJzWVc1 MElHbHUgSU ZCMVpYSjBi eSBCU2FXTn ZManhpIGNq NHhNQzRnU1 cgNGdNakF5 TUN3ZyBSMn hoZUc5VGJX IGwwYUV0c2 FXNWwgSUdK bFkyRnRaUy BCMGFHVWda bWx5IGMzUW djR2hoY20g MWhZMlYxZE dsaiBZV3dn WTI5dGNHIE Z1ZVNCMGJ5 QncgYkdWa1 oyVWdkRyA4 Z2JXRnJaU0 JwIGRITWdZ MkZ5WW0gOX VJR1p2YjNS dyBjbWx1ZE NCdVpYIFF0 ZW1WeWJ5Qm kgZVNBeU1E VXdMaiB4aW NqNHhNUzRn IFIyeGhlRz lUYlcgbDBh RXRzYVc1bC BJR2hoY3lC aElIIE4wY2 05dVp5Qmog YjIxdGFYUn RaVyA1MElI UnZJR052IG NuQnZjbUYw WlMgQnpiMk 5wWVd3ZyBj bVZ6Y0c5dW MyIGxpYVd4 cGRIa3MgSU hkcGRHZ2dZ UyBCbWIyTj FjeUJ2IGJp QnBiWEJ5Yj MgWnBibWNn WjJ4diBZbU ZzSUdobFlX IHgwYUN3Z2 NtVmsgZFdO cGJtY2dhWC BSeklHVnVk bWx5IGIyNX RaVzUwWVcg d2dhVzF3WV dOMCBMQ0Jo Ym1RZ2MzIF Z3Y0c5eWRH bHUgWnlCam IyMXRkVyA1 cGRHbGxjeU IzIGFHVnla U0JwZEMgQn ZjR1Z5WVhS bCBjeTQ4WW 5JK01UIEl1 SUZSb1pTQm ogYjIxd1lX NTVJRyBoaG N5QmhJR1Jw IGRtVnljMl VnZDIgOXlh Mlp2Y21ObC BMQ0IzYVhS b0lHIDkyWl hJZ01UQXcg TERBd01DQm xiWCBCc2Iz bGxaWE1nIG QyOXliR1Iz YVcgUmxJR0 Z1WkNCaCBJ SE4wY205dV p5IEJtYjJO MWN5QnYgYm lCa2FYWmxj biBOcGRIa2 dZVzVrIElH bHVZMngxYz IgbHZiaUJw YmlCMCBhR1 VnZDI5eWEz IEJzWVdObE xqeGkgY2o0 eE15NGdSMi B4aGVHOVRi V2wwIGFFdH NhVzVsSUcg aGhjeUJoSU hKdiBZblZ6 ZENCd2FYIE JsYkdsdVpT QnYgWmlCdV pYY2daSCBK MVozTWdZVz VrIElIUnla V0YwYlcgVn VkSE1nYVc0 ZyBaR1YyWl d4dmNHIDFs Ym5Rc0lIZH AgZEdnZ2Iz WmxjaSBBMU 1DQmpZVzVr IGFXUmhkR1 VnZEcgaGxj bUZ3YVdWei BJR2x1SUha aGNtIGx2ZF hNZ2MzUmgg WjJWeklHOW 1JRyBOc2FX NXBZMkZzIE lIUnlhV0Zz Y3kgNDhZbk krTVRRdSBJ RlJvWlNCam IyIDF3WVc1 NUlHaGggY3 lCaElITjBj bSA5dVp5Qn djbVZ6IFpX NWpaU0J2Ym kgQnpiMk5w WVd3ZyBiV1 ZrYVdFc0lI IGRwZEdnZ2 IzWmwgY2lB NE5Td3dNRC BBZ1ptOXNi RzkzIFpYSn pJRzl1SUYg UjNhWFIwWl hJZyBZVzVr SUdGamRHIG wyWlNCaFky TnYgZFc1MG N5QnZiaSBC TWFXNXJaV1 JKIGJpd2dS bUZqWlcgSn ZiMnNzSUdG dSBaQ0JKYm 5OMFlXIGR5 WVcwdVBHSn kgUGpFMUxp QkhiRyBGNG IxTnRhWFJv IFMyeHBibV VnYUcgRnpJ SEpsWTJWcC BkbVZrSUc1 MWJXIFZ5Yj NWeklHRjMg WVhKa2N5Qm hibSBRZ2Nt VmpiMmR1IG FYUnBiMjRn Wm0gOXlJR2 wwY3lCMyBi M0pyTENCcG JtIE5zZFdS cGJtY2cgWW 1WcGJtY2di bSBGdFpXUW diMjVsIElH OW1JSFJvWl MgRGlnSnhY YjNKcyBaT0 tBbVhNZ1RX IDl6ZENCRm RHaHAgWTJG c0lFTnZiWC BCaGJtbGxj K0tBIG5TQm llU0IwYUcg VWdSWFJvYV hOdyBhR1Z5 WlNCSmJuIE 4wYVhSMWRH VWcgWm05eU lERXhJRyBO dmJuTmxZM1 YwIGFYWmxJ SGxsWVggSn pMZz09CiAg ICAgICAgPC 9zcGFuPgog ICAgICAgIA ogICAgICAg IA==